Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
January 12 2010 - 6:30AM
PR Newswire (US)
NEW YORK, Jan. 12 /PRNewswire-FirstCall/ -- Delcath Systems, Inc.
(NASDAQ: DCTH) announced today that it will present at the 12th
Annual Needham Growth Stock Conference at the New York Palace
Hotel. The Company's presentation is scheduled for 4:30 p.m.
Eastern Time on January 14, 2010. David McDonald, Chief Financial
Officer, will review the company's business strategy and recent
corporate developments. Delcath will offer a live video webcast of
its presentation which may be accessed on the Investor Relations
section of the Company's website at http://www.delcath.com/. An
archived replay of the presentation will be available for 30 days,
also at http://www.delcath.com/. About Delcath Systems, Inc.
Delcath Systems, Inc. is a medical device company specializing in
cancer treatment. The Company is testing a proprietary, patented
drug delivery system for the treatment of liver cancers. Delcath's
novel drug delivery platform is testing the delivery of ultra-high
doses of anti-cancer drugs to the liver while preventing these high
doses of drug from entering the patient's bloodstream. The Company
is currently enrolling patients in Phase III and Phase II clinical
studies for the treatment of liver cancers using high doses of
melphalan. The Company maintains a broad intellectual property
portfolio on a worldwide basis including the U.S., Europe, Asia and
Canada. For more information, please visit the Company's website at
http://www.delcath.com/. The Private Securities Litigation Reform
Act of 1995 provides a safe harbor for forward-looking statements
made by the Company or on its behalf. This news release contains
forward-looking statements, which are subject to certain risks and
uncertainties that can cause actual results to differ materially
from those described. Factors that may cause such differences
include, but are not limited to, uncertainties relating to our
ability to successfully complete Phase III clinical trials and
secure regulatory approval of our current or future drug-delivery
system and uncertainties regarding our ability to obtain financial
and other resources for any research, development and
commercialization activities. These factors, and others, are
discussed from time to time in our filings with the Securities and
Exchange Commission. You should not place undue reliance on these
forward-looking statements, which speak only as of the date they
are made. We undertake no obligation to publicly update or revise
these forward-looking statements to reflect events or circumstances
after the date they are made. DATASOURCE: Delcath Systems, Inc.
CONTACT: Investors, Doug Sherk or Stacey Fisher, +1-415-896-6820,
or Media, Steve DiMattia, +1-646-201-5445, all of EVC Group, for
Delcath Systems, Inc. Web Site: http://www.delcath.com/
Copyright